470 related articles for article (PubMed ID: 27512927)
1. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis.
Elfert A; Abo Ali L; Soliman S; Ibrahim S; Abd-Elsalam S
Eur J Gastroenterol Hepatol; 2016 Dec; 28(12):1450-1454. PubMed ID: 27512927
[TBL] [Abstract][Full Text] [Related]
2. The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients.
Mostafa T; Badra G; Abdallah M
Turk J Gastroenterol; 2015 Mar; 26(2):163-9. PubMed ID: 25835116
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: a prospective randomized open-label comparative multicenter study.
Assem M; Elsabaawy M; Abdelrashed M; Elemam S; Khodeer S; Hamed W; Abdelaziz A; El-Azab G
Hepatol Int; 2016 Mar; 10(2):377-85. PubMed ID: 26660707
[TBL] [Abstract][Full Text] [Related]
4. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin.
Novella M; Solà R; Soriano G; Andreu M; Gana J; Ortiz J; Coll S; Sàbat M; Vila MC; Guarner C; Vilardell F
Hepatology; 1997 Mar; 25(3):532-6. PubMed ID: 9049193
[TBL] [Abstract][Full Text] [Related]
5. Addition of probiotics to norfloxacin does not improve efficacy in the prevention of spontaneous bacterial peritonitis: a double-blind placebo-controlled randomized-controlled trial.
Pande C; Kumar A; Sarin SK
Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):831-9. PubMed ID: 22522141
[TBL] [Abstract][Full Text] [Related]
6. The role of rifaximine in the prevention of the spontaneous bacterial peritonitis.
Dănulescu RM; Ciobică A; Stanciu C; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2013; 117(2):315-20. PubMed ID: 24340510
[TBL] [Abstract][Full Text] [Related]
7. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis.
Hanouneh MA; Hanouneh IA; Hashash JG; Law R; Esfeh JM; Lopez R; Hazratjee N; Smith T; Zein NN
J Clin Gastroenterol; 2012 Sep; 46(8):709-15. PubMed ID: 22878533
[TBL] [Abstract][Full Text] [Related]
8. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites.
Lutz P; Parcina M; Bekeredjian-Ding I; Nischalke HD; Nattermann J; Sauerbruch T; Hoerauf A; Strassburg CP; Spengler U
PLoS One; 2014; 9(4):e93909. PubMed ID: 24714550
[TBL] [Abstract][Full Text] [Related]
9. Norfloxacin and cisapride combination decreases the incidence of spontaneous bacterial peritonitis in cirrhotic ascites.
Sandhu BS; Gupta R; Sharma J; Singh J; Murthy NS; Sarin SK
J Gastroenterol Hepatol; 2005 Apr; 20(4):599-605. PubMed ID: 15836710
[TBL] [Abstract][Full Text] [Related]
10. Daily Norfloxacin vs. Weekly Ciprofloxacin to Prevent Spontaneous Bacterial Peritonitis: A Randomized Controlled Trial.
Yim HJ; Suh SJ; Jung YK; Yim SY; Seo YS; Lee YR; Park SY; Jang JY; Kim YS; Kim HS; Kim BI; Um SH
Am J Gastroenterol; 2018 Aug; 113(8):1167-1176. PubMed ID: 29946179
[TBL] [Abstract][Full Text] [Related]
11. Role of Rifaximin in Spontaneous Bacterial Peritonitis Prevention.
Oliver A; Wong M; Sanchez C
South Med J; 2018 Nov; 111(11):660-665. PubMed ID: 30392000
[TBL] [Abstract][Full Text] [Related]
12. Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis.
Soni H; Kumar-M P; Sharma V; Bellam BL; Mishra S; Mahendru D; Mandavdhare HS; Medhi B; Dutta U; Singh V
Hepatol Int; 2020 May; 14(3):399-413. PubMed ID: 32266675
[TBL] [Abstract][Full Text] [Related]
13. Spontaneous bacterial peritonitis recurrence in patients with cirrhosis receiving secondary prophylaxis with norfloxacin.
Marciano S; Dirchwolf M; Diaz JM; Bermudez C; Gutierrez-Acevedo MN; Barcán LA; Smud A; Giunta D; Gadano AC
Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):540-546. PubMed ID: 30557229
[TBL] [Abstract][Full Text] [Related]
14. Trimethoprim-sulfamethoxazole versus norfloxacin in the prophylaxis of spontaneous bacterial peritonitis in cirrhosis.
Alvarez RF; Mattos AA; Corrêa EB; Cotrim HP; Nascimento TV
Arq Gastroenterol; 2005; 42(4):256-62. PubMed ID: 16444382
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Rifaximin in Prophylaxis of Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-analysis.
Menshawy A; Mattar O; Barssoum K; AboEl-Naga AM; Salim HM; Mohamed AMF; Elgebaly A; Abd-Elsalam S
Curr Drug Targets; 2019; 20(4):380-387. PubMed ID: 30246636
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy of long-term antibiotic treatments in the primary prophylaxis of spontaneous bacterial peritonitis.
Facciorusso A; Papagiouvanni I; Cela M; Buccino VR; Sacco R
Liver Int; 2019 Aug; 39(8):1448-1458. PubMed ID: 30920712
[TBL] [Abstract][Full Text] [Related]
17. Norfloxacin and trimethoprim-sulfamethoxazole therapy have similar efficacy in prevention of spontaneous bacterial peritonitis.
Lontos S; Gow PJ; Vaughan RB; Angus PW
J Gastroenterol Hepatol; 2008 Feb; 23(2):252-5. PubMed ID: 17559367
[TBL] [Abstract][Full Text] [Related]
18. Norfloxacin vs ceftriaxone in the prophylaxis of infections in patients with advanced cirrhosis and hemorrhage.
Fernández J; Ruiz del Arbol L; Gómez C; Durandez R; Serradilla R; Guarner C; Planas R; Arroyo V; Navasa M
Gastroenterology; 2006 Oct; 131(4):1049-56; quiz 1285. PubMed ID: 17030175
[TBL] [Abstract][Full Text] [Related]
19. Rifaximin Vs. Norfloxacin for Spontaneous Bacterial Peritonitis Prophylaxis: A Randomized Controlled Trial.
Praharaj DL; Premkumar M; Roy A; Verma N; Taneja S; Duseja A; Dhiman RK
J Clin Exp Hepatol; 2022; 12(2):336-342. PubMed ID: 35535057
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.
Kang SH; Lee YB; Lee JH; Nam JY; Chang Y; Cho H; Yoo JJ; Cho YY; Cho EJ; Yu SJ; Kim MY; Kim YJ; Baik SK; Yoon JH
Aliment Pharmacol Ther; 2017 Nov; 46(9):845-855. PubMed ID: 28836723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
